Advertisement
News
Advertisement

Cancer: OncoSec lands EU approval for tumor-treating immunotherapy

Fri, 10/19/2012 - 10:29am
Mass Device

OncoSec wins CE Mark approval for its OMS system that delivery electrical pulses to tumors to make the cells more vulnerable to anti-cancer agents.

OncoSec logo

OncoSec Medical (OTC:ONCS) won CE Mark approval in the European Union for its gene- and drug-delivery platform, the OncoSec Medical System.

The OMS product is an electroporation device, which targets a tumor with short electrical pulses that opens pores and allows anti-cancer agents to more effectively destroy the cells.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading